The growth of the field of tissue engineering over the past several decades has been remarkable. While considerable investments continue to be placed in research and development for tissue engineering technologies, translation of the technologies to the clinic to effect patient care remains the ultimate objective.
A recent article by Kim et al. presents an overview of the tissue engineering market in the United States from 2011 to 2018, as guided by information gleaned from publically available financial disclosures and clinical trial databases. The overview highlights the dominance of biomaterial-based products in the current tissue engineering marketplace, while stem cell-based companies dominate research and development spending. The article suggests potential for continued revenue growth in the tissue engineering market in coming years, but it underscores the importance of dynamic regulatory policies and reimbursement strategies on influencing market viability of tissue engineering products.
An Overview of the Tissue Engineering Market in the United States from 2011 to 2018.
Kim YS, Smoak MM, Melchiorri AJ, Mikos AG. Tissue Eng Part A. 2019 Jan;25(1-2):1-8. doi: 10.1089/ten.TEA.2018.0138.